For myhairline.ai’s deep dive, context is the difference between useful guidance and another anxiety spiral. Pattern, density, age, family history, and treatment tolerance all matter before anyone jumps to a product or procedure.
A friend of mine, a 28-year-old software developer named Dan, showed me a photo on his phone last winter. It was a selfie taken under his bathroom’s overhead light, the kind of unflattering angle that reveals every bit of scalp showing through thinning hair. “My barber told me to look into finasteride,” he said, a little embarrassed, like he’d been caught worrying about something trivial. Dan’s question was simple: what is this drug actually doing, biologically? It’s a question I hear constantly, and answering it properly means starting with the hormone that makes pattern hair loss happen in the first place.
Dihydrotestosterone (DHT) is the androgen responsible for follicular miniaturization, the slow shrinking of hair follicles that drives androgenetic alopecia. DHT-blocking medications, principally finasteride and dutasteride, work by inhibiting the 5-alpha reductase enzyme that converts testosterone into DHT. That’s the one-sentence version. The full picture takes a bit more space.
How We Got the Classification (and Why It Still Matters)
Pattern hair loss has been formally studied since James Hamilton’s 1951 paper in the Annals of the New York Academy of Sciences. Hamilton’s key insight was elegantly simple: men castrated before puberty did not develop the recession and crown thinning typical of androgenetic alopecia. No androgens, no balding. That observation established the hormonal basis of the condition.
O’Tar Norwood built on Hamilton’s work in a 1975 paper in the Southern Medical Journal, expanding a rough three-stage framework into the seven-stage system (with several variant subtypes, including the Type A pattern where loss advances primarily from the front) that dermatologists still use. The combined Hamilton-Norwood scale has survived for more than 70 years because it does something hard: it captures enough of the natural variation to be clinically useful while remaining simple enough that two different doctors looking at the same scalp will usually agree on the stage. Modern alternatives, including the basic and specific (BASP) classification proposed in 2007, haven’t displaced it in routine practice.
Understanding where you sit on that scale is the first practical step. The biology of DHT, the enzyme that produces it, and the medications that block it all plug into this broader diagnostic framework.
See also: How Technology Is Enhancing Workplace Communication
What DHT Actually Does to Your Hair Follicles
Here’s the mechanism, stripped down.
Testosterone circulates in the blood. In certain tissues (scalp skin among them), the enzyme 5-alpha reductase converts testosterone into DHT, which is roughly five times more potent as an androgen. In genetically susceptible follicles, DHT binds to the androgen receptor in the dermal papilla and sets off a chain of changes across successive hair cycles.
The anagen (growth) phase gets shorter. The telogen (resting) phase gets longer. The dermal papilla itself physically shrinks. Over time, hairs that were once thick and pigmented become progressively thinner, shorter, and eventually wispy vellus hairs that contribute almost nothing to visible coverage. That process is follicular miniaturization, and it is the core pathology of pattern hair loss.
The genetics behind this are polygenic. The androgen receptor gene on the X chromosome is one contributor, which is where the “look at your mom’s dad” rule of thumb comes from. But paternal side genetics and other autosomal loci matter too, so family history is a clue, not a verdict.
Two drugs exploit this biology directly. Finasteride inhibits the type II isoform of 5-alpha reductase, reducing scalp DHT. Dutasteride inhibits both type I and type II isoforms, producing a more aggressive DHT reduction and, in head-to-head trials, larger improvements in hair density. For a more granular walkthrough of the DHT-blocking pathway and how it maps to clinical staging, Myhairline.ai’s deep dive covers the detail with photographic examples and stage-by-stage interpretation.
Diagnosis Is More Than Looking in the Mirror
The American Academy of Dermatology’s clinical guidelines for hair loss evaluation emphasize a structured approach that goes well beyond glancing at the hairline.
A proper workup includes patient history (timeline of loss, medications, recent illnesses, dietary changes), family history, scalp examination, and trichoscopy, which is essentially dermoscopy applied to the scalp. Trichoscopy picks up things the naked eye misses. In androgenetic alopecia, you’ll see hair shaft diameter variability (caliber variability of 20% or more), yellow dots representing empty follicular ostia, and reduced follicular unit density in affected areas with the occipital donor zone still intact.
Lab work is selective. Ferritin, TSH, vitamin D, and a CBC make sense when telogen effluvium is suspected or the thinning is diffuse. The AAD does not recommend routine androgen panels in men with classic pattern loss. The diagnosis is clinical.
Standardized photography (front, top, sides, back, consistent distance and lighting, reproducible head position) is the boring-but-essential tool for tracking change over months. I’d argue that every patient starting treatment should take these photos on day one, even if it feels uncomfortable. Without a baseline, you’re guessing.
What the Evidence Supports, and What It Costs
Treatment works best when started early, before significant follicular loss has occurred. There is no intervention that resurrects a truly dead follicle. Here’s a practical breakdown of what the literature supports.
Oral finasteride 1 mg daily has the largest evidence base. The five-year randomized trial published in the Journal of the American Academy of Dermatology (JAAD) in 2002 showed sustained improvements in hair count and patient self-assessment versus placebo. Sexual dysfunction, the side effect that dominates online discussion, affects a small percentage of users in randomized trials and is generally reversible on discontinuation. Generic finasteride runs $10 to $25 monthly at US pharmacies with discount cards, sometimes $5 to $15 through direct-to-consumer telehealth. Branded Propecia costs $70 to $90 monthly with no documented clinical advantage. The boring truth: generic finasteride is one of the best cost-to-efficacy ratios in all of dermatology.
Topical minoxidil 5% is FDA-approved for over-the-counter use. Its mechanism isn’t fully understood but appears to involve potassium channel opening, vasodilation, and a direct follicle effect that prolongs anagen. Response typically becomes visible at three to six months. Generic costs $10 to $30 monthly. Foam and solution are clinically equivalent.
Low-dose oral minoxidil (0.25 to 5 mg daily) gained traction after Vañó-Galván et al.’s 2021 multicenter study of 1,404 patients in JAAD documented efficacy at lower doses than the original cardiovascular formulation. The side-effect profile at these doses is more manageable than originally feared, though periorbital edema and hypertrichosis show up. Generic, often under $15/month.
Dutasteride is approved for benign prostatic hypertrophy and used off-label for hair loss. Olsen et al. (JAAD, 2006) reported that dual 5-alpha reductase inhibition produced larger DHT reductions and greater hair density improvements than finasteride alone.
Platelet-rich plasma (PRP) and microneedling have a modest evidence base as adjuncts. JAMA Dermatology has published smaller randomized trials with positive but variable results. PRP runs $500 to $1,500 per session, with most protocols recommending three to four sessions in the first year. The total first-year cost can equal or exceed an entire year of combination medical therapy, which is worth thinking about.
Hair transplantation (FUE or FUT) is the only option that physically moves follicles from the resistant donor zone to thinning areas. In the US, FUE typically costs $4 to $10 per graft. A typical 2,500 to 3,500 graft case runs $10,000 to $35,000. Turkish clinics charge $2,000 to $5,000 total for similar graft counts, reflecting labor cost differences, not necessarily quality differences. Most experienced surgeons want you on medical therapy first to stabilize the native hair, especially if you’re under 30.
Insurance generally classifies pattern hair loss treatment as cosmetic. HSA and FSA accounts may cover prescribed medications and physician visits but typically not surgery.
Lifestyle Factors: What Actually Moves the Needle
Pattern hair loss is genetically determined. No amount of kale smoothies will override your androgen receptor sensitivity. But several factors influence the rate of shedding, and the peer-reviewed literature (primarily in JAAD and the International Journal of Trichology) supports a few clear conclusions.
Smoking accelerates hair loss through microvascular damage, oxidative stress, and effects on circulating androgens. Cross-sectional studies show higher rates of androgenetic alopecia in smokers versus matched nonsmokers.
Iron deficiency (serum ferritin below 30 ng/mL in women, below 50 ng/mL when hair loss is a concern) contributes to shedding via telogen effluvium. Iron repletion in deficient patients reduces shedding. Iron supplementation in iron-replete patients does nothing.
Severe stress can precipitate telogen effluvium starting two to three months after the precipitating event. This typically resolves within six to nine months once the stressor resolves, though it can unmask underlying pattern loss.
Anabolic steroid use accelerates pattern hair loss in susceptible men through supraphysiologic androgen exposure. The effects may not be fully reversible after discontinuation. Think of it like pouring gasoline on a fire that was always going to burn, just burning it ten times faster.
Severe caloric restriction and rapid weight loss reliably produce telogen effluvium. Modest dietary tweaks beyond correcting deficiencies won’t produce visible hair benefits.
When You Need a Dermatologist, Not a Search Engine
Self-management is reasonable in many cases, but certain scenarios call for an in-person evaluation.
Sudden, diffuse shedding that started within the last six months suggests telogen effluvium and needs workup for the precipitating cause. Patchy, smooth, well-circumscribed bald spots suggest alopecia areata, an autoimmune condition with a completely different treatment pathway. Scalp pain, burning, redness, scaling, or visible scarring could indicate a scarring alopecia (lichen planopilaris, frontal fibrosing alopecia, central centrifugal cicatricial alopecia) where prompt diagnosis matters because destroyed follicles are gone for good (Kassira et al., JAAD, 2017). Hair loss in women with menstrual irregularities, acne, or excess body hair warrants endocrine evaluation for PCOS or other androgen excess states.
The AAD’s position: any progressive hair loss that is concerning to the patient is a legitimate reason for consultation. That’s a low bar, and intentionally so.
FAQs
Should I get a hair transplant if I am in my 20s?
Experienced surgeons approach transplantation in patients in their 20s cautiously because the long-term loss pattern isn’t yet established. The priority is usually medical therapy to stabilize native hair first, then reassess.
Is hair loss covered by insurance?
Pattern hair loss treatment is generally classified as cosmetic and not covered. Some HSA and FSA accounts will cover prescribed medications and physician visits.
Can diet alone slow hair loss?
Diet can address contributing factors like iron deficiency or severe caloric restriction, but it does not stop the underlying genetic process of androgenetic alopecia.
Can stress cause permanent hair loss?
Severe stress can trigger telogen effluvium, a temporary diffuse shedding that typically resolves within six to nine months. Stress does not directly cause androgenetic alopecia, though it can unmask or accelerate underlying pattern loss in susceptible individuals.
How fast does pattern hair loss progress?
It varies enormously. Some men progress one Norwood stage every few years. Others remain stable for long periods. Age of onset, family history, and the rate of recent change are the strongest predictors of future trajectory.
Are hair transplants permanent?
Transplanted follicles from the genetically resistant donor zone generally retain their resistance to miniaturization and persist long-term. But the surrounding native hair may continue to thin, which is why most patients continue medical therapy after transplantation.
Does wearing a hat cause hair loss?
No. This is one of the most persistent myths. Hats do not cause androgenetic alopecia. Extremely tight headgear worn constantly could theoretically contribute to traction alopecia, but your baseball cap is not the problem.
References
- Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53(3):708-728.
- Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359-1365.
- Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men: short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22.
- American Academy of Dermatology Association. Hair loss: diagnosis and treatment. AAD clinical guidance.
- Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss. J Am Acad Dermatol. 2006;55(6):1014-1023.
- Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104-109.
- Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651.
- Gentile P, Garcovich S. Systematic review of platelet-rich plasma use in androgenetic alopecia compared with minoxidil, finasteride, and adult stem cell-based therapy. Int J Mol Sci. 2020;21(8):2702.
- Kassira S, Korta DZ, Chapman LW, Dann F. Frontal fibrosing alopecia: a review. J Am Acad Dermatol. 2017;77(2):209-212.
- Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786.
Educational content, not medical advice. This article summarizes peer-reviewed sources and clinical guidelines for general informational purposes and does not constitute medical advice, diagnosis, or treatment. Hair loss has multiple possible causes, and an in-person dermatology evaluation is the appropriate starting point for any individual case. Do not start, stop, or change medications based on this article.
Privacy framing for AI-based assessment tools: AI hair-loss screening tools such as Myhairline.ai analyze user-submitted photos using MediaPipe Face Mesh 468-landmark detection. Photos are not stored, and no account is required. The AI output is educational, not diagnostic.
